Always talk to your doctor first

This page lists trials that are available to patients with FCS.  Please check the location of trial sites.

Choosing to participate in a trial is an important personal decision so it is important to talk with your doctor and family members or friends when deciding whether to join a trial.

To learn more about a trial, you or your doctor may contact the trial research staff using the Contacts provided.

Learn more about clinical trials on the website.

Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS): Akcea Pharmaceuticals, Inc

The Program is intended to provide expanded access to volanesorsen for eligible patients with FCS who have limited or no available treatment options.

Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.

Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS) (PALISADE): Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is currently enrolling its Phase 3 study in FCS patients. The purpose or AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all protocol eligibility criteria will be randomized to receive 4 total doses of ARO-APOC3 or matching placebo administered subcutaneously.

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome: Akcea Pharmaceuticals, Inc

This is a multi-center, open-label study for Group 1: ISIS 304801-CS6 (index study) roll-over FCS patients, Group 2: ISIS 304801-CS16 (index study) roll-over FCS patients, and Group 3: FCS patients who did not participate in the ISIS 304801-CS6 or ISIS 304801-CS16 index studies. All patients will receive volanesorsen 300 mg once per week for 52 weeks. Patients will have the option of continuing dosing for an additional 52 weeks until an expanded access program is approved and available in their country.

Trials sites are located at various locations across the world.

More in About FCS